deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT03062059

The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence

The Effectiveness and Safety of Intravesical Gemcitabine Instillation During Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma: Prospective, Phase II Study

Sponsor: Asan Medical Center

Conditions Urothelial Carcinoma
Interventions Intravesical 2000mg/52.6ml gemcitabine instillation Normal saline
Updated 9 times since 2017 Last updated: Apr 6, 2022 Started: Mar 1, 2018 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Urothelial Carcinoma, this trial is ongoing. The trial is conducted by Asan Medical Center and has accumulated 9 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshotRecruiting~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotRecruiting~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotRecruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotRecruiting~May 2022 – ~May 2024 · 24 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. May 2024 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  5. May 2022 — May 2024 [monthly]

    Recruiting PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Recruiting PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  3. Jun 2018 — Apr 2020 [monthly]

    Recruiting PHASE2

  4. Mar 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Asan Medical Center
  • Chong Kun Dang Pharmaceutical Corp.
  • Korea University Anam Hospital
  • National Cancer Center, Korea
  • Samsung Medical Center
  • Seoul National University Hospital
Data source: National Cancer Center, Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations